Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

184.02 +2.34 (+1.29%)
Official Closing Price Updated: 7:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
80 81 Next >
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQ:SRPT) and its peers. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race
AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market. 
Via Benzinga
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.
This is the drugmaker's first foray into weight-loss drugs. And it's not focusing on GLP-1. 
Via Investor's Business Daily
These Vanguard ETFs Show Where the Smart Money Is Moving Now
Via The Motley Fool
Topics ETFs
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
Via Benzinga
How Is The Market Feeling About AbbVie?
Via Benzinga
4 Sectors That Thrive When Inflation Runs Hot
Sticky inflation and higher-for-longer interest rates is causing a rotation out of technology stocks, here are four sectors for investors hunting for value 
Via MarketBeat
Topics Economy World Trade
Exposures Interest Rates Tariff
3 Reasons ABBV is Risky and 1 Stock to Buy Instead
AbbVie trades at $205.51 per share and has stayed right on track with the overall market, gaining 5.2% over the last six months. At the same time, the S&P 500 has returned 5.1%. 
Via StockStory
Topics Stocks
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Via The Motley Fool
Is AbbVie Stock a Buy Now?
Via The Motley Fool
2 High-Yield Dividend ETFs to Buy to Generate Passive Income
With yields ranging between 3.6% and 7.3%, these dividend ETFs are great bets for generating passive income. 
Via The Motley Fool
Topics ETFs
Gilead Sciences: 4 Reasons This Stock Has Much More To Rise
Gilead Pharmaceuticals is back to highs not seen in a decade as its HIV treatment franchise surges and awaits its 100% effective HIV prevention drug in summer 
Via MarketBeat
Topics Death
Exposures Death
Large Cap Biopharmaceutical Metrics And Performance Q1 2025
Tariffs could have big impact on earnings in 2025. 
Via Talk Markets
Topics Stocks / Equities
2 Magnificent Dividend Growth Stocks to Load Up On Right Now
Via The Motley Fool
4 Stocks and 1 Exchange-Traded Fund (ETF) I Can't Stop Buying
Five great investments for any portfolio. 
Via The Motley Fool
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results tomorrow afternoon. Here’s what you need to know. 
Via StockStory
Trump's Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich
Robert Reich has termed Donald Trump's taxation policies as an "absolutely shameless giveaway," that could shoot up deficit to $4.6 trillion. 
Via Benzinga
Topics Government
Exposures Political
Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday?
AbbVie and Xilio partner to develop tumor-activated immunotherapies. Xilio's pipeline includes masked T cell engagers for prostate, gastric, and lung cancers. 
Via Benzinga
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
From Xilio Therapeutics, Inc.; AbbVie Inc.
Via GlobeNewswire
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect
Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow morning. Here’s what to look for. 
Via StockStory
Healthcare And Biotech Playbook As Disruption Gathers Force
The XBI was down 1.54% for the week, like off a cliff on Friday from a Wednesday high of $94.82. 
Via Talk Markets
Topics ETFs Stocks / Equities
These Stocks Missed on Earnings, But Will Rebound Next Quarter
Here are three stocks from companies that missed on earnings but have strong support from analysts that makes each stock a solid Buy for the next year 
Via MarketBeat
Gilead Sciences (GILD) Q4 Earnings: What To Expect
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what to expect. 
Via StockStory
3 Fabulous Dividend Stocks to Buy in February
Via The Motley Fool
Vertex Pharmaceuticals (VRTX) Q4 Earnings Report Preview: What To Look For
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for. 
Via StockStory
Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings tomorrow before the bell. Here’s what to expect. 
Via StockStory
3 Dividend Stocks to Double Up on Right Now
Via The Motley Fool
These 2 Dividend Stocks Are Absolute Bargains Right Now
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
80 81 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS